Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222537 | 0.81 | LMNA (0.40) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL29168008 | 0.81 | LMNA (0.37) | LMNAMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15417666 | 0.81 | LMNA (0.43) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL13270149 | 0.78 | LMNA (0.41) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL5632040 | 0.78 | POLB (0.39) | LMNAMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24777113 | 0.77 | POLB (0.41) | LMNAMAPTPOLBKMT2AKDM4E | |
| SCHEMBL6020809 | 0.77 | MAPT (0.37) | LMNAMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18775161 | 0.77 | IRAK4 (0.41) | LMNAMAPTPOLBKDM4EPRMT6 | |
| SCHEMBL10716962 | 0.76 | POLB (0.39) | LMNAMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22111912 | 0.76 | LMNA (0.39) | LMNAMAPTSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022092084-A1 | FUSED HETEROCYCLE DERIVATIVE AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | クミアイ化学工業株式会社 | 2022-05-05 | — | — | WO | disclosed |
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2628726-A1 | Hydroxamate-based inhibitors of deacetylases b | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8349883-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| EP-2260020-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | LMNA 1633/4885MAPT 3582/4885SLC6A2 2823/4885 |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | LMNA 1633/4885MAPT 3582/4885SLC6A2 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.